GlassScriptPhysician profile
Lindsey Rose
NPI 1659878692
$731.69
in general payments reported to CMS, 2019-2025
12 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $234 · 2024: $292 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $289.98 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $93.29 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $61.10 | 2024 | Eliquis |
| Lilly USA, LLC | $59.05 | 2024 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $44.23 | 2023-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $40.19 | 2023 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $36.78 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.22 | 2024-2025 | Xifaxan |
| Tms Neurohealth Centers INC. | $24.01 | 2025 | Tms Neurohealth Centers INC. |
| Amgen INC. | $17.73 | 2023 | Otezla, Repatha |
| Phadia US INC. | $16.31 | 2025 | Immunocap |
| Insulet Corporation | $15.80 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.